Literature DB >> 24821775

Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.

Behzad Kharabi Masouleh1, Huimin Geng2, Christian Hurtz2, Lai N Chan2, Aaron C Logan3, Mi Sook Chang4, Chuanxin Huang5, Srividya Swaminathan2, Haibo Sun6, Elisabeth Paietta7, Ari M Melnick5, Phillip Koeffler6, Markus Müschen8.   

Abstract

The unfolded protein response (UPR) pathway, a stress-induced signaling cascade emanating from the endoplasmic reticulum (ER), regulates the expression and activity of molecules including BiP (HSPA5), IRE1 (ERN1), Blimp-1 (PRDM1), and X-box binding protein 1 (XBP1). These molecules are required for terminal differentiation of B cells into plasma cells and expressed at high levels in plasma cell-derived multiple myeloma. Although these molecules have no known role at early stages of B-cell development, here we show that their expression transiently peaks at the pre-B-cell receptor checkpoint. Inducible, Cre-mediated deletion of Hspa5, Prdm1, and Xbp1 consistently induces cellular stress and cell death in normal pre-B cells and in pre-B-cell acute lymphoblastic leukemia (ALL) driven by BCR-ABL1- and NRAS(G12D) oncogenes. Mechanistically, expression and activity of the UPR downstream effector XBP1 is regulated positively by STAT5 and negatively by the B-cell-specific transcriptional repressors BACH2 and BCL6. In two clinical trials for children and adults with ALL, high XBP1 mRNA levels at the time of diagnosis predicted poor outcome. A small molecule inhibitor of ERN1-mediated XBP1 activation induced selective cell death of patient-derived pre-B ALL cells in vitro and significantly prolonged survival of transplant recipient mice in vivo. Collectively, these studies reveal that pre-B ALL cells are uniquely vulnerable to ER stress and identify the UPR pathway and its downstream effector XBP1 as novel therapeutic targets to overcome drug resistance in pre-B ALL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24821775      PMCID: PMC4040579          DOI: 10.1073/pnas.1400958111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Jinghui Zhang; Charles G Mullighan; Richard C Harvey; Gang Wu; Xiang Chen; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Meenakshi Devidas; Daniela S Gerhard; Mignon L Loh; Gregory H Reaman; Mary V Relling; Bruce M Camitta; W Paul Bowman; Malcolm A Smith; Cheryl L Willman; James R Downing; Stephen P Hunger
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

2.  Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma.

Authors:  Ioanna Papandreou; Nicholas C Denko; Michael Olson; Heleen Van Melckebeke; Sofie Lust; Arvin Tam; David E Solow-Cordero; Donna M Bouley; Fritz Offner; Maho Niwa; Albert C Koong
Journal:  Blood       Date:  2010-11-16       Impact factor: 22.113

3.  Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

Authors:  Dejan Juric; Norman J Lacayo; Meghan C Ramsey; Janis Racevskis; Peter H Wiernik; Jacob M Rowe; Anthony H Goldstone; Peter J O'Dwyer; Elisabeth Paietta; Branimir I Sikic
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

4.  GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development.

Authors:  Shengzhan Luo; Changhui Mao; Brenda Lee; Amy S Lee
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

5.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Authors:  Andrea Hoelbl; Christian Schuster; Boris Kovacic; Bingmei Zhu; Mark Wickre; Maria A Hoelzl; Sabine Fajmann; Florian Grebien; Wolfgang Warsch; Gabriele Stengl; Lothar Hennighausen; Valeria Poli; Hartmut Beug; Richard Moriggl; Veronika Sexl
Journal:  EMBO Mol Med       Date:  2010-03       Impact factor: 12.137

6.  BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Authors:  Charles G Mullighan; Christopher B Miller; Ina Radtke; Letha A Phillips; James Dalton; Jing Ma; Deborah White; Timothy P Hughes; Michelle M Le Beau; Ching-Hon Pui; Mary V Relling; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2008-04-13       Impact factor: 49.962

Review 7.  Fine-tuning of the unfolded protein response: Assembling the IRE1alpha interactome.

Authors:  Claudio Hetz; Laurie H Glimcher
Journal:  Mol Cell       Date:  2009-09-11       Impact factor: 17.970

8.  BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.

Authors:  Cihangir Duy; Christian Hurtz; Seyedmehdi Shojaee; Leandro Cerchietti; Huimin Geng; Srividya Swaminathan; Lars Klemm; Soo-mi Kweon; Rahul Nahar; Melanie Braig; Eugene Park; Yong-mi Kim; Wolf-Karsten Hofmann; Sebastian Herzog; Hassan Jumaa; H Phillip Koeffler; J Jessica Yu; Nora Heisterkamp; Thomas G Graeber; Hong Wu; B Hilda Ye; Ari Melnick; Markus Müschen
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

9.  Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.

Authors:  Michael A Dengler; Annette M Staiger; Matthias Gutekunst; Ute Hofmann; Malgorzata Doszczak; Peter Scheurich; Matthias Schwab; Walter E Aulitzky; Heiko van der Kuip
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

10.  XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development.

Authors:  Derrick J Todd; Louise J McHeyzer-Williams; Czeslawa Kowal; Ann-Hwee Lee; Bruce T Volpe; Betty Diamond; Michael G McHeyzer-Williams; Laurie H Glimcher
Journal:  J Exp Med       Date:  2009-09-14       Impact factor: 14.307

View more
  46 in total

1.  Novel Gene and Network Associations Found for Acute Lymphoblastic Leukemia Using Case-Control and Family-Based Studies in Multiethnic Populations.

Authors:  Priyanka Nakka; Natalie P Archer; Heng Xu; Philip J Lupo; Benjamin J Raphael; Jun J Yang; Sohini Ramachandran
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-27       Impact factor: 4.254

Review 2.  Endoplasmic reticulum proteostasis: a key checkpoint in cancer.

Authors:  Scott A Oakes
Journal:  Am J Physiol Cell Physiol       Date:  2016-11-16       Impact factor: 4.249

Review 3.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

Review 4.  TUSC3: functional duality of a cancer gene.

Authors:  Kateřina Vašíčková; Peter Horak; Petr Vaňhara
Journal:  Cell Mol Life Sci       Date:  2017-09-19       Impact factor: 9.261

5.  Inhibition of the hexosamine biosynthesis pathway potentiates cisplatin cytotoxicity by decreasing BiP expression in non-small-cell lung cancer cells.

Authors:  Wenshu Chen; Kieu C Do; Bryanna Saxton; Shuguang Leng; Piotr Filipczak; Mathewos Tessema; Steven A Belinsky; Yong Lin
Journal:  Mol Carcinog       Date:  2019-03-06       Impact factor: 4.784

6.  Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells.

Authors:  Chih-Hang Anthony Tang; Joseph A Zundell; Sujeewa Ranatunga; Cindy Lin; Yulia Nefedova; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  Cancer Res       Date:  2016-03-07       Impact factor: 12.701

7.  WNT16-expressing Acute Lymphoblastic Leukemia Cells are Sensitive to Autophagy Inhibitors after ER Stress Induction.

Authors:  Meletios Verras; Ioanna Papandreou; Nicholas C Denko
Journal:  Anticancer Res       Date:  2015-09       Impact factor: 2.480

8.  X-Box-Binding Protein 1 and Innate Immune Responses of Human Cystic Fibrosis Alveolar Macrophages.

Authors:  Bob A Lubamba; Lisa C Jones; Wanda K O'Neal; Richard C Boucher; Carla M P Ribeiro
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

9.  Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress.

Authors:  Guy J Leclerc; Joanna DeSalvo; Jianfeng Du; Ningguo Gao; Gilles M Leclerc; Mark A Lehrman; Theodore J Lampidis; Julio C Barredo
Journal:  Leuk Res       Date:  2015-08-20       Impact factor: 3.156

Review 10.  Unfolded Protein Response in Leukemia: From Basic Understanding to Therapeutic Opportunities.

Authors:  Ali Khateb; Ze'ev A Ronai
Journal:  Trends Cancer       Date:  2020-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.